Philip Astley-Sparke 5.0 1 idea

The FDA rejection of Replimune's melanoma drug was unfair because the drug has strong efficacy data with a 34% remission rate and durable responses, it resensitizes patients to anti-PD-1 therapy, and has broad support from oncologists and patient advocacy groups, indicating that the drug should be approved and the company has promising prospects.